{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T14:03:18Z","timestamp":1794405798687,"version":"4.9.0"},"reference-count":75,"publisher":"Bentham Science Publishers Ltd.","issue":"26","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CTMC"],"published-print":{"date-parts":[[2020,11,3]]},"abstract":"<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>Growing concern about neurodegenerative diseases is becoming a global issue. It is estimated\nthat not only will their prevalence increase but also morbidity and health burden will be concerning. Scientists,\nresearchers and clinicians share the responsibility of raising the awareness and knowledge about\nthe restricting and handicapping health restrains related to these diseases.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>Multiple Sclerosis (MS), as one of the prevalent autoimmune diseases, is characterized by abnormal\nregulation of the immune system that periodically attacks parts of the nervous system; brain and spinal\ncord. Symptoms and impairments include weakness, numbness, visual problems, tingling pain that are\nquietly variable among patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>Amyotrophic Lateral Sclerosis (ALS) is another neurodegenerative disease that is characterized by the\ndegeneration of motor neurons in the brain and spinal cord. Unlike MS, symptoms begin with muscle\nweakness and progress to affect speech, swallowing and finally breathing. Despite the major differences\nbetween MS and ALS, misdiagnosis is still influencing disease prognosis and patient\u2019s quality of life.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>Diagnosis depends on obtaining a careful history and neurological examination as well as the use of\nMagnetic Resonance Imaging (MRI), which are considered challenging and depend on the current disease\nstatus in individuals.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>Fortunately, a myriad of treatments is available now for MS. Most of the cases are steroid responsive.\nDisease modifying therapy is amongst the most important set of treatments.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>In ALS, few medications that slow down disease progression are present. The aim of this paper is to\nsummarize what has been globally known and practiced about MS and ALS, as they are currently classified\nas important growing key players among autoimmune diseases. In terms of treatments, it is concluded\nthat special efforts and input should be directed towards repurposing of older drugs and on stem\ncells trials. As for ALS, it is highlighted that supportive measurements and supplementary treatments\nremain essentially needed for ALS patients and their families. On the other hand, it is noteworthy to\nclarify that the patient-doctor communication is relatively a cornerstone in selecting the best treatment\nfor each MS patient.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1568026620666200924114827","type":"journal-article","created":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T04:59:29Z","timestamp":1601009969000},"page":"2391-2403","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Exploring Multiple Sclerosis (MS) and Amyotrophic Lateral Scler osis (ALS) as Neurodegenerative Diseases and their Treatments: A Review Study"],"prefix":"10.2174","volume":"20","author":[{"given":"Omar","family":"Deeb","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy, Al-Quds University, P.O. Box 20002 Jerusalem, Palestinian Territory, Occupied"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maisa","family":"Nabulsi","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Al-Quds University, P.O. Box 20002 Jerusalem, Palestinian Territory, Occupied"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.3892\/mmr.2016.4948","volume":"13","author":"Chen W.W.","year":"2016","unstructured":"Chen W.W.; Zhang X.; Huang W.J.; Role of neuroinflammation in neurodegenerative diseases. (Review) Mol Med Rep 2016,13(4),3391-3396","journal-title":"Mol Med Rep"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"6587","DOI":"10.1523\/JNEUROSCI.0529-11.2011","volume":"31","author":"McClean P.L.","year":"2011","unstructured":"McClean P.L.; Parthsarathy V.; Faivre E.; H\u00f6lscher C.; The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer\u2019s disease. J Neurosci 2011,31(17),6587-6594","journal-title":"J Neurosci"},{"key":"ref=3","author":"Osakwe O.","year":"2016","unstructured":"Osakwe O.; Rizvi S.A.A.;  Social Aspects of Drug Discovery, Development and Commercialization 2016","journal-title":"Social Aspects of Drug Discovery, Development and Commercialization"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ph11020044","volume":"11","author":"Dur\u00e3es F.","year":"2018","unstructured":"Dur\u00e3es F.; Pinto M.; Sousa E.; Old drugs as new treatments for neurodegenerative diseases. Pharmaceuticals (Basel) 2018,11(2),1-21","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.2147\/NDT.S140634","volume":"13","author":"Luo C.","year":"2017","unstructured":"Luo C.; Jian C.; Liao Y.; Huang Q.; Wu Y.; Liu X.; Zou D.; Wu Y.; The role of microglia in multiple sclerosis. Neuropsychiatr Dis Treat 2017,13,1661-1667","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1002\/jnr.20488","volume":"81","author":"Ponomarev E.D.","year":"2005","unstructured":"Ponomarev E.D.; Shriver L.P.; Maresz K.; Dittel B.N.; Microglial cell activation and proliferation precedes the onset of CNS autoimmunity. J Neurosci Res 2005,81(3),374-389","journal-title":"J Neurosci Res"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1750-3639.2007.00064.x","volume":"17","author":"Lassmann H.","year":"2007","unstructured":"Lassmann H.; Br\u00fcck W.; Lucchinetti C.F.; The immunopathology of multiple sclerosis: an overview. Brain Pathol 2007,17(2),210-218","journal-title":"Brain Pathol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1177\/1352458518809296","volume":"25","author":"Segal B.M.","year":"2019","unstructured":"Segal B.M.; Enhancing natural killer cells is beneficial in multiple sclerosis - Commentary. Mult Scler 2019,25(4),513-514","journal-title":"Mult Scler"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"I21","DOI":"10.1007\/s00415-006-1105-z","volume":"253","author":"Merkelbach S.","year":"2006","unstructured":"Merkelbach S.; Haensch C.A.; Hemmer B.; Koehler J.; K\u00f6nig N.H.; Ziemssen T.; Multiple sclerosis and the autonomic nervous system. J Neurol 2006,253(1)(Suppl. 1),I21-I25","journal-title":"J Neurol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1146\/annurev.neuro.30.051606.094313","volume":"31","author":"Trapp B.D.","year":"2008","unstructured":"Trapp B.D.; Nave K-A.; Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci 2008,31(1),247-269","journal-title":"Annu Rev Neurosci"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3389\/fneur.2019.00045","volume":"10","author":"Hu C.J.","year":"2019","unstructured":"Hu C.J.; Octave J.N.; Editorial: Risk factors and outcome predicating biomarker of neurodegenerative diseases. Front Neurol 2019,10,45","journal-title":"Front Neurol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S1474-4422(14)70267-4","volume":"14","author":"Belbasis L.","year":"2015","unstructured":"Belbasis L.; Bellou V.; Evangelou E.; Ioannidis J.P.A.; Tzoulaki I.; Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses. Lancet Neurol 2015,14(3),263-273","journal-title":"Lancet Neurol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1177\/1352458517737371","volume":"24","author":"Canto E.","year":"2018","unstructured":"Canto E.; Oksenberg J.R.; Multiple sclerosis genetics. Mult Scler 2018,24(1),75-79","journal-title":"Mult Scler"},{"key":"ref=14","first-page":"3","volume":"29","author":"Gilmour H.","year":"2018","unstructured":"Gilmour H.; Ramage-Morin P.L.; Wong S.L.; Multiple sclerosis: Prevalence and impact. Health Rep 2018,29(1),3-8","journal-title":"Health Rep"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1093\/brain\/awv078","volume":"138","author":"Isobe N.","year":"2015","unstructured":"Isobe N.; Madireddy L.; Khankhanian P.; Matsushita T.; Caillier S.J.; Mor\u00e9 J.M.; Gourraud P.A.; McCauley J.L.; Beecham A.H.; Piccio L.; Herbert J.; Khan O.; Cohen J.; Stone L.; Santaniello A.; Cree B.A.; Onengut-Gumuscu S.; Rich S.S.; Hauser S.L.; Sawcer S.; Oksenberg J.R.; An ImmunoChip study of multiple sclerosis risk in African Americans. Brain International Multiple Sclerosis Genetics Consortium2015,138(Pt 6),1518-1530","journal-title":"Brain"},{"key":"ref=16","doi-asserted-by":"crossref","unstructured":"komori M., Blake A., Greenwood M et al, Cerebrospinal fluid markers reveal intrathecal inflamation in progressive multiple sclerosis. Ann Neurol., 2015, 78(1), 3-20","DOI":"10.1002\/ana.24408"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1146\/annurev.med.53.082901.103909","volume":"53","author":"Keegan B.M.","year":"2002","unstructured":"Keegan B.M.; Noseworthy J.H.; Multiple sclerosis. Annu Rev Med 2002,53,285-302","journal-title":"Annu Rev Med"},{"key":"ref=18","first-page":"175","volume":"37","author":"Goldenberg M.M.","year":"2012","unstructured":"Goldenberg M.M.; Multiple sclerosis review. P 2012,37(3),175-184","journal-title":"P"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","volume":"83","author":"Lublin F.D.","year":"2014","unstructured":"Lublin F.D.; Reingold S.C.; Cohen J.A.; Cutter G.R.; S\u00f8rensen P.S.; Thompson A.J.; Wolinsky J.S.; Balcer L.J.; Banwell B.; Barkhof F.; Bebo B.; Calabresi P.A.; Clanet M.; Comi G.; Fox R.J.; Freedman M.S.; Goodman A.D.; Inglese M.; Kappos L.; Kieseier B.C.; Lincoln J.A.; Lubetzki C.; Miller A.E.; Montalban X.; O\u2019Connor P.W.; Petkau J.; Pozzilli C.; Rudick R.A.; Sormani M.P.; St\u00fcve O.; Waubant E.; Polman C.H.; Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 2014,83(3),278-286","journal-title":"Neurology"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000367614","volume":"72","author":"Lublin F.D.","year":"2014","unstructured":"Lublin F.D.; New multiple sclerosis phenotypic classification. Eur Neurol 2014,72(Suppl. 1),1-5","journal-title":"Eur Neurol"},{"key":"ref=21","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000530","volume":"6","author":"Hemond C.C.","year":"2019","unstructured":"Hemond C.C.; Healy B.C.; Tauhid S.; Mazzola M.A.; Quintana F.J.; Gandhi R.; Weiner H.L.; Bakshi R.; MRI phenotypes in MS: Longitudinal changes and miRNA signatures. Neurol Neuroimmunol Neuroinflamm 2019,6(2)","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1212\/CON.0000000000000737","volume":"25","author":"Kantarci O.H.","year":"2019","unstructured":"Kantarci O.H.; Phases and phenotypes of multiple sclerosis. Continuum (Minneap Minn) 2019,25(3),636-654","journal-title":"Continuum (Minneap Minn)"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1055\/s-2007-1019124","volume":"28","author":"Bar-Or A.","year":"2008","unstructured":"Bar-Or A.; The immunology of multiple sclerosis. Semin Neurol 2008,28(1),29-45","journal-title":"Semin Neurol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1503\/cmaj.130727","volume":"186","author":"Tavazzi E.","year":"2014","unstructured":"Tavazzi E.; Rovaris M.; La Mantia L.; Drug therapy for multiple sclerosis. CMAJ 2014,186(11),833-840","journal-title":"CMAJ"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.18553\/jmcp.2016.22.12.1394","volume":"22","author":"Higuera L.","year":"2016","unstructured":"Higuera L.; Carlin C.S.; Anderson S.; Adherence to disease-modifying therapies for multiple sclerosis. J Manag Care Spec Pharm 2016,22(12),1394-1401","journal-title":"J Manag Care Spec Pharm"},{"key":"ref=26","first-page":"S28","volume":"19","author":"Mathis A.S.","year":"2013","unstructured":"Mathis A.S.; Managed care aspects of managing multiple sclerosis. Am J Manag Care 2013,19(2)(Suppl.),S28-S34","journal-title":"Am J Manag Care"},{"key":"ref=27","first-page":"644","volume":"90","author":"Saguil A.","year":"2014","unstructured":"Saguil A.; Kane S.; Farnell E.; Multiple sclerosis: a primary care perspective. Am Fam Physician 2014,90(9),644-652","journal-title":"Am Fam Physician"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2147\/PPA.S118107","volume":"11","author":"Munsell M.","year":"2016","unstructured":"Munsell M.; Frean M.; Menzin J.; Phillips A.L.; An evaluation of adherence in patients with multiple sclerosis newly initiating treatment with a self-injectable or an oral disease-modifying drug. Patient Prefer Adherence 2016,11,55-62","journal-title":"Patient Prefer Adherence"},{"key":"ref=29","first-page":"S15","volume":"55","year":"2018","unstructured":"\u00d6. Recent advances in the treatment for multiple sclerosis; current new drugs specific for multiple sclerosis. Noro Psikiyatri Arsivi Ta\u015eKapilio\u011eLu2018,55(Suppl. 1),S15-S20","journal-title":"Noro Psikiyatri Arsivi"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1007\/s00415-017-8505-0","volume":"264","author":"Lattanzi S.","year":"2017","unstructured":"Lattanzi S.; Cagnetti C.; Danni M.; Provinciali L.; Silvestrini M.; Oral and intravenous steroids for multiple sclerosis relapse: a systematic review and meta-analysis. J Neurol 2017,264(8),1697-1704","journal-title":"J Neurol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1177\/1352458514531088","volume":"20","author":"Chataway J.","year":"2014","unstructured":"Chataway J.; Oral versus intravenous steroids in multiple sclerosis relapses - a perennial question? Mult Scler 2014,20(6),643-645","journal-title":"Mult Scler"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1191\/1352458505ms1190oa","volume":"11","author":"Sloka J.S.","year":"2005","unstructured":"Sloka J.S.; Stefanelli M.; The mechanism of action of methylprednisolone in the treatment of multiple sclerosis. Mult Scler 2005,11(4),425-432","journal-title":"Mult Scler"},{"key":"ref=33","author":"Therapy D.","unstructured":"Therapy D.; Multiple F.O.R.;  Drug therapy for multiple myeloma American Cancer Society, 2020. Available from:","journal-title":"Drug therapy for multiple myeloma"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","volume":"90","author":"Rae-Grant A.","year":"2018","unstructured":"Rae-Grant A.; Day G.S.; Marrie R.A.; Rabinstein A.; Cree B.A.C.; Gronseth G.S.; Haboubi M.; Halper J.; Hosey J.P.; Jones D.E.; Lisak R.; Pelletier D.; Potrebic S.; Sitcov C.; Sommers R.; Stachowiak J.; Getchius T.S.D.; Merillat S.A.; Pringsheim T.; Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 2018,90(17),777-788","journal-title":"Neurology"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"264","DOI":"10.4103\/0972-2327.58283","volume":"12","author":"Ontaneda D.","year":"2009","unstructured":"Ontaneda D.; Rae-Grant A.D.; Management of acute exacerbations in multiple sclerosis. Ann Indian Acad Neurol 2009,12(4),264-272","journal-title":"Ann Indian Acad Neurol"},{"key":"ref=36","volume":"1","author":"La Mantia L.","year":"2007","unstructured":"La Mantia L.; Milanese C.; Mascoli N.; D\u2019Amico R.; Weinstock-Guttman B.; Cyclophosphamide for multiple sclerosis. Cochrane Database Syst Rev 2007,1","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1177\/1756285609344375","volume":"2","author":"Awad A.","year":"2009","unstructured":"Awad A.; St\u00fcve O.; Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms. Ther Adv Neurol Disorder 2009,2(6),50-61","journal-title":"Ther Adv Neurol Disorder"},{"key":"ref=38","first-page":"28","volume":"33","author":"Robertson D.","year":"2016","unstructured":"Robertson D.; Moreo N.; Disease-modifying therapies in multiple sclerosis: overview and treatment considerations. Fed Pract 2016,33(6),28-34","journal-title":"Fed Pract"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/B978-0-444-52001-2.00021-2","volume":"122","author":"O\u2019Connor P.W.","year":"2014","unstructured":"O\u2019Connor P.W.; Oh J.; Disease-modifying agents in multiple sclerosis. Handb Clin Neurol 2014,122,465-501","journal-title":"Handb Clin Neurol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1212\/WNL.0b013e3181c97d99","volume":"74","author":"Dhib-Jalbut S.","year":"2010","unstructured":"Dhib-Jalbut S.; Marks S.; Interferon-beta mechanisms of action in multiple sclerosis. Neurology 2010,74(Suppl. 1),S17-S24","journal-title":"Neurology"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1093\/brain\/aww037","volume":"139","author":"Kilsdonk I.D.","year":"2016","unstructured":"Kilsdonk I.D.; Jonkman L.E.; Klaver R.; van Veluw S.J.; Zwanenburg J.J.M.; Kuijer J.P.A.; Pouwels P.J.; Twisk J.W.; Wattjes M.P.; Luijten P.R.; Barkhof F.; Geurts J.J.; Increased cortical grey matter lesion detection in multiple sclerosis with 7 T MRI: a post-mortem verification study. Brain 2016,139(Pt 5),1472-1481","journal-title":"Brain"},{"key":"ref=42","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004678.pub2","volume":"5","author":"La Mantia L.","year":"2010","unstructured":"La Mantia L.; Munari L.M.; Lovati R.; Glatiramer acetate for multiple sclerosis. Cochrane Database Syst Rev 2010,5(5)","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1017\/S0317167100053804","volume":"31","author":"Freedman MS.","year":"2004","unstructured":"Freedman MS.; Patry D.G.; Grand\u2019Maison F.; Myles M.L.; Paty D.W.; Selchen D.H.; Canadian M.S.; Working Group. Treatment optimization in multiple sclerosis. Can J Neurol Sci 2004,31(2),157-168","journal-title":"Can J Neurol Sci"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1136\/bmj.321.7259.490","volume":"321","author":"Polman C.H.","year":"2000","unstructured":"Polman C.H.; Uitdehaag B.M.J.; Drug treatment of multiple sclerosis. BMJ 2000,321(7259),490-494","journal-title":"BMJ"},{"key":"ref=45","unstructured":"Multiple Sclerosis Association of America"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","volume":"391","author":"Kappos L.","year":"2018","unstructured":"Kappos L.; Bar-Or A.; Cree B.A.C.; Fox R.J.; Giovannoni G.; Gold R.; Vermersch P.; Arnold D.L.; Arnould S.; Scherz T.; Wolf C.; Wallstr\u00f6m E.; Dahlke F.; Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet EXPAND Clinical Investigators2018,391(10127),1263-1273","journal-title":"Lancet"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1056\/NEJMoa0902533","volume":"362","author":"Giovannoni G.","year":"2010","unstructured":"Giovannoni G.; Comi G.; Cook S.; Rammohan K.; Rieckmann P.; Soelberg S\u00f8rensen P.; Vermersch P.; Chang P.; Hamlett A.; Musch B.; Greenberg S.J.; A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med CLARITY Study Group2010,362(5),416-426","journal-title":"N Engl J Med"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1007\/s13311-017-0573-4","volume":"14","author":"Giovannoni G.","year":"2017","unstructured":"Giovannoni G.; Cladribine to treat relapsing forms of multiple sclerosis. Neurotherapeutics 2017,14(4),874-887","journal-title":"Neurotherapeutics"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.2147\/NDT.S114636","volume":"13","author":"Brandstadter R.","year":"2017","unstructured":"Brandstadter R.; Katz Sand I.; The use of natalizumab for multiple sclerosis. Neuropsychiatr Dis Treat 2017,13,1691-1702","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"Hauser S.L.","year":"2017","unstructured":"Hauser S.L.; Bar-Or A.; Comi G.; Giovannoni G.; Hartung H.P.; Hemmer B.; Lublin F.; Montalban X.; Rammohan K.W.; Selmaj K.; Traboulsee A.; Wolinsky J.S.; Arnold D.L.; Klingelschmitt G.; Masterman D.; Fontoura P.; Belachew S.; Chin P.; Mairon N.; Garren H.; Kappos L.; OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med 2017,376(3),221-234","journal-title":"N Engl J Med"},{"key":"ref=51","doi-asserted-by":"publisher","DOI":"10.1177\/1756286418773025","volume":"11","author":"Mulero P.","year":"2018","unstructured":"Mulero P.; Midaglia L.; Montalban X.; Ocrelizumab: a new milestone in multiple sclerosis therapy. Ther Adv Neurol Disorder 2018,11","journal-title":"Ther Adv Neurol Disorder"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"339","DOI":"10.2147\/TCRM.S85099","volume":"12","author":"Prosperini L.","year":"2016","unstructured":"Prosperini L.; Pontecorvo S.; Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations. Ther Clin Risk Manag 2016,12,339-350","journal-title":"Ther Clin Risk Manag"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1191\/1352458505ms1173oa","volume":"11","author":"R\u00edo J.","year":"2005","unstructured":"R\u00edo J.; Porcel J.; T\u00e9llez N.; S\u00e1nchez-Betancourt A.; Tintor\u00e9 M.; Ar\u00e9valo M.J.; Nos C.; Montalban X.; Factors related with treatment adherence to interferon \u03b2 and glatiramer acetate therapy in multiple sclerosis. Mult Scler 2005,11(3),306-309","journal-title":"Mult Scler"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"545","DOI":"10.12998\/wjcc.v3.i7.545","volume":"3","author":"Gajofatto A.","year":"2015","unstructured":"Gajofatto A.; Benedetti M.D.; Treatment strategies for multiple sclerosis: When to start, when to change, when to stop? World J Clin Cases 2015,3(7),545-555","journal-title":"World J Clin Cases"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/s41598-018-35734-4","volume":"9","author":"Hooijmans C.R.","year":"2019","unstructured":"Hooijmans C.R.; Hlavica M.; Schuler F.A.F.; Good N.; Good A.; Baumgartner L.; Galeno G.; Schneider M.P.; Jung T.; de Vries R.; Ineichen B.V.; Remyelination promoting therapies in multiple sclerosis animal models: a systematic review and meta-analysis. Sci Rep 2019,9(1),822-839","journal-title":"Sci Rep"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1001\/jama.2014.9799","volume":"312","author":"Horton D.K.","year":"2014","unstructured":"Horton D.K.; Mehta P.; Antao V.C.; Quantifying a nonnotifiable disease in the United States: the national amyotrophic lateral sclerosis registry model. JAMA 2014,312(11),1097-1098","journal-title":"JAMA"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1750-1172-4-3","volume":"4","author":"Wijesekera L.C.","year":"2009","unstructured":"Wijesekera L.C.; Leigh P.N.; Amyotrophic lateral sclerosis. Orphanet J Rare Dis 2009,4(1),3","journal-title":"Orphanet J Rare Dis"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.3390\/ijms20112616","volume":"20","author":"Nowicka N.","year":"2019","unstructured":"Nowicka N.; Juranek J.; Juranek J.K.; Wojtkiewicz J.; Risk factors and emerging therapies in amyotrophic lateral sclerosis. Int J Mol Sci 2019,20(11),2616","journal-title":"Int J Mol Sci"},{"key":"ref=59","first-page":"1027","volume":"138","author":"Bonduelle M.","year":"1982","unstructured":"Bonduelle M.; Amyotrophic lateral sclerosis. Rev Neurol (Paris) 1982,138(12),1027-1039","journal-title":"Rev Neurol (Paris)"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1136\/jnnp.2009.183525","volume":"81","author":"Logroscino G.","year":"2010","unstructured":"Logroscino G.; Traynor B.J.; Hardiman O.; Chi\u00f2 A.; Mitchell D.; Swingler R.J.; Millul A.; Benn E.; Beghi E.; EURALS. Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry 2010,81(4),385-390","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/362059a0","volume":"362","author":"Rosen D.R.","year":"1993","unstructured":"Rosen D.R.; Siddique T.; Patterson D.; Figlewicz D.A.; Sapp P.; Hentati A.; Donaldson D.; Goto J.; O\u2019Regan J.P.; Deng H.X.; Mutations in Cu\/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993,362(6415),59-62","journal-title":"Nature"},{"key":"ref=62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.17352\/2455-2976.000020","volume":"3","author":"Cacciapuoti F.","year":"2016","unstructured":"Cacciapuoti F.; Oxidative stress as \u201cmother\u201d of many human diseases at strong clinical impact. J Cardiovasc Med Cardiol 2016,3,1-6","journal-title":"J Cardiovasc Med Cardiol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"189","DOI":"10.4103\/1673-5374.244782","volume":"14","author":"Fogarty M.J.","year":"2019","unstructured":"Fogarty M.J.; Amyotrophic lateral sclerosis as a synaptopathy. Neural Regen Res 2019,14(2),189-192","journal-title":"Neural Regen Res"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1021\/ci400128m","volume":"53","author":"Tubert-Brohman I.","year":"2013","unstructured":"Tubert-Brohman I.; Sherman W.; Repasky M.; Beuming T.; Improved docking of polypeptides with Glide. J Chem Inf Model 2013,53(7),1689-1699","journal-title":"J Chem Inf Model"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2147\/DNND.S120607","volume":"7","author":"Ngo S.T.","year":"2017","unstructured":"Ngo S.T.; Mi J.D.; Henderson R.D.; McCombe P.A.; Steyn F.J.; Exploring targets and therapies for amyotrophic lateral sclerosis: current insights into dietary interventions. Degener Neurol Neuromuscul Dis 2017,7,95-108","journal-title":"Degener Neurol Neuromuscul Dis"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/17482968.2010.502940","volume":"12","author":"Beghi E.","year":"2011","unstructured":"Beghi E.; Chi\u00f2 A.; Couratier P.; Esteban J.; Hardiman O.; Logroscino G.; Millul A.; Mitchell D.; Preux P.M.; Pupillo E.; Stevic Z.; Swingler R.; Traynor B.J.; Van den Berg L.H.; Veldink J.H.; Zoccolella S.; The epidemiology and treatment of ALS: focus on the heterogeneity of the disease and critical appraisal of therapeutic trials. Amyotroph Lateral Scler Eurals Consortium2011,12(1),1-10","journal-title":"Amyotroph Lateral Scler"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1080\/17482960801900032","volume":"9","author":"Orrell R.W.","year":"2008","unstructured":"Orrell R.W.; Lane R.J.M.; Ross M.; A systematic review of antioxidant treatment for amyotrophic lateral sclerosis\/motor neuron disease. Amyotroph Lateral Scler 2008,9(4),195-211","journal-title":"Amyotroph Lateral Scler"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S1474-4422(18)30091-7","volume":"17","author":"Dharmadasa T.","year":"2018","unstructured":"Dharmadasa T.; Kiernan M.C.; Riluzole, disease stage and survival in ALS. Lancet Neurol 2018,17(5),385-386","journal-title":"Lancet Neurol"},{"key":"ref=69","first-page":"25","volume":"43","author":"Cruz M.P.","year":"2018","unstructured":"Cruz M.P.; Edaravone (Radicava): A novel neuroprotective agent for the treatment of amyotrophic lateral sclerosis. P 2018,43(1),25-28","journal-title":"P"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1358\/dot.2018.54.6.2828189","volume":"54","author":"Bhandari R.","year":"2018","unstructured":"Bhandari R.; Kuhad A.; Kuhad A.; Edaravone: a new hope for deadly amyotrophic lateral sclerosis. Drugs Today (Barc) 2018,54(6),349-360","journal-title":"Drugs Today (Barc)"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s00011-019-01310-3","volume":"69","author":"Faissner S.","year":"2020","unstructured":"Faissner S.; Letter to the editor regarding Gholamzad et al., \u201cA comprehensive review on the treatment approaches of multiple sclerosis: currently and in the future. Inflamm Res 2020,69(2),153","journal-title":"Inflamm Res"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"171","DOI":"10.4103\/2152-7806.169561","volume":"6","author":"Zarei S.","year":"2015","unstructured":"Zarei S.; Carr K.; Reiley L.; Diaz K.; Guerra O.; Altamirano P.F.; Pagani W.; Lodin D.; Orozco G.; Chinea A.; A comprehensive review of amyotrophic lateral sclerosis. Surg Neurol Int 2015,6(1),171","journal-title":"Surg Neurol Int"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/S1474-4422(14)70068-7","volume":"13","author":"Calabresi P.A.","year":"2014","unstructured":"Calabresi P.A.; Kieseier B.C.; Arnold D.L.; Balcer L.J.; Boyko A.; Pelletier J.; Liu S.; Zhu Y.; Seddighzadeh A.; Hung S.; Deykin A.; Pegylated interferon \u03b2-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol ADVANCE Study Investigators2014,13(7),657-665","journal-title":"Lancet Neurol"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","volume":"380","author":"Cohen J.A.","year":"2012","unstructured":"Cohen J.A.; Coles A.J.; Arnold D.L.; Confavreux C.; Fox E.J.; Hartung H.P.; Havrdova E.; Selmaj K.W.; Weiner H.L.; Fisher E.; Brinar V.V.; Giovannoni G.; Stojanovic M.; Ertik B.I.; Lake S.L.; Margolin D.H.; Panzara M.A.; Compston D.A.; CARE-MS I investigators. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012,380(9856),1819-1828","journal-title":"Lancet"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","volume":"380","author":"Coles A.J.","year":"2012","unstructured":"Coles A.J.; Twyman C.L.; Arnold D.L.; Cohen J.A.; Confavreux C.; Fox E.J.; Hartung H.P.; Havrdova E.; Selmaj K.W.; Weiner H.L.; Miller T.; Fisher E.; Sandbrink R.; Lake S.L.; Margolin D.H.; Oyuela P.; Panzara M.A.; Compston D.A.; CARE-MS II investigators. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012,380(9856),1829-1839","journal-title":"Lancet"}],"container-title":["Current Topics in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/186248","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/186248\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/186248","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T12:20:41Z","timestamp":1619180441000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/186248\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,3]]},"references-count":75,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2020,11,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1568026620666200924114827","relation":{},"ISSN":["1568-0266"],"issn-type":[{"value":"1568-0266","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-06-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-31","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}